An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)

Conclusion: These results suggest that the LFC formulation of pexmetinib may achieve greater exposures with lower doses due to the greater bioavailability compared to the PIC, and remain unaffected by coadministration with food. Keywords: pexmetinib, myelodysplastic syndromes, liquid-filled capsule, bioavailability, food-effect, formulation 
Source: International Journal of COPD - Category: Respiratory Medicine Tags: Clinical Pharmacology: Advances and Applications Source Type: research